WCLC 2025 - Posters & ePosters-EP.12.43 Long Progression-Free Survival With Sunvozertinib in EGFRm NSCLC Patients After Third-Generation EGFR TKI Failure: Case Series

EP.12.43 Long Progression-Free Survival With Sunvozertinib in EGFRm NSCLC Patients After Third-Generation EGFR TKI Failure: Case Series

Back to course

Pdf Summary

This retrospective case series reports on the clinical efficacy and safety of sunvozertinib, an oral, highly selective EGFR-TKI approved for advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations, in three EGFR-mutated (EGFRm) NSCLC patients who experienced treatment failure following third-generation EGFR TKI therapy. The patients, aged 61 to 72 years, all had adenocarcinoma and were treated with sunvozertinib either as monotherapy (225-300 mg once daily) or combined with vinorelbine.<br /><br />All three patients achieved long progression-free survival (PFS) ranging from 12 to 13 months while maintaining stable disease status. Adverse events reported during treatment were mild and manageable, including diarrhea, paronychia, fatigue, and poor appetite, with no new safety signals observed.<br /><br />These real-world findings align with previous data demonstrating sunvozertinib's durable antitumor activity in EGFRm NSCLC patients who failed standard EGFR TKI therapy, suggesting its potential as an effective subsequent treatment option after third-generation EGFR TKI resistance. Given the limited sample size, the authors recommend further prospective studies with larger cohorts to better establish the therapeutic value and safety profile of sunvozertinib in this patient population.<br /><br />In summary, this case series highlights sunvozertinib's promising clinical benefit and acceptable safety as a viable treatment strategy for EGFRm NSCLC patients following failure of third-generation EGFR TKIs.

Asset Subtitle

Mengxing You

Meta Tag

Speaker Mengxing You

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

sunvozertinib

EGFR-TKI

non-small cell lung cancer

NSCLC

EGFR exon 20 insertion mutations

third-generation EGFR TKI resistance

adenocarcinoma

progression-free survival

treatment safety

vinorelbine